Johnson & Johnson, a major healthcare company, has lowered its 2026 profit forecast. The company cited the financial impact of its recent acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines as the reason for the reduction.
The company now expects full-year adjusted earnings per share of $10.96 to $11.11, down from its previous forecast of $11.60 to $11.75. The two transactions are expected to reduce the company’s 2026 adjusted earnings by about $0.64 per share.
Despite the lowered profit forecast, Johnson & Johnson kept its annual revenue expectations intact at $100.8 billion to $101.4 billion. The company also said the Sail and Firefly deals were expected to impact 2027 adjusted earnings by $1.36 per share.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.